Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of various therapeutics in the United States. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and Iclusig, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a drug in Phase III clinical trial for steroid-refractory chronic graft-versus-host-diseases (GVHD); and Phase II trial for the treatment of essential thrombocythemia and refractory myelofibrosis. In addition, the company engages in the development of itacitinib, which is in Phase III clinical trial to treat naÃ¯ve chronic GVHD; and pemigatinib that is in Phase II clinical trial for treating bladder cancer, cholangiocarcinoma, 8p11 myeloproliferative syndrome, and Tumor agnostic. Further, it is involved in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, the company develops INCMGA0012 that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Merus N.V.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; MorphoSys AG; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; and Zai Lab Limited, as well as a clinical collaboration with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1991 and is headquartered in Wilmington, Delaware.

Date	Fund	Action	%
2023/07/25	ARKG	Buy	0.2457
2023/07/11	ARKG	Sell	0.176
2023/05/11	ARKG	Sell	0.207
2023/05/10	ARKG	Sell	0.0367
2023/05/09	ARKG	Sell	0.0463
2023/05/08	ARKG	Sell	0.0906
2023/05/05	ARKG	Sell	0.2723
2023/05/04	ARKG	Sell	0.0193
2023/05/03	ARKG	Sell	0.0775
2023/04/05	ARKG	Sell	0.1011
2023/03/31	ARKG	Sell	0.101
2023/03/28	ARKG	Sell	0.2822
2023/03/27	ARKG	Sell	0.0154
2023/02/27	ARKG	Sell	0.1246
2023/02/23	ARKG	Sell	0.0142
2023/02/22	ARKG	Sell	0.056
2023/02/06	ARKG	Sell	0.1369
2023/02/03	ARKG	Sell	0.0188
2023/02/01	ARKG	Sell	0.042
2022/08/18	ARKG	Sell	0.1399
2022/08/17	ARKG	Sell	0.0603
2022/08/16	ARKG	Sell	1.6215
2022/03/07	ARKG	Sell	0.1187
2022/03/03	ARKG	Sell	0.4865
2021/07/19	ARKG	Buy	0.1974
2021/01/27	ARKG	Buy	0.0897
2021/01/26	ARKG	Buy	0.0904
2021/01/25	ARKG	Buy	0.0294
2021/01/22	ARKG	Buy	0.1694
2021/01/21	ARKG	Buy	0.1836